Prime Medicine expects first approval next year for chronic granulomous disease; Wilson disease Phase 1-2 began dosing in October and targets 2027 data, while alpha-1 antitrypsin’s first patient dose is expected end of the year or soon after.
PRME · Prime Medicine, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As a result, we concluded that substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $3.84
- Open
- $3.84
- Day range
- $3.69–4.07
- 52-week closing range
- $2.70–5.36
- Average volume, 30 days
- 5.6M
- Short interest
- 29.1M · 16.0% of shares · 4.8 days
- Short volume, last session
- 48%
- Last earnings
- Nov 12, 2025
- Latest filing
- 10-Q · Nov 12
- Price history
- Oct 2022 to Nov 2026
Latest documents
Prime Medicine, Inc. concluded substantial doubt exists about its ability to continue as a going concern for 12 months, reporting $61.2 million in cash, cash equivalents and short-term investments as of September 30, 2026, and $74.8 million including restricted cash.
Prime Medicine raised $143.7 million in gross proceeds, reporting pro-forma cash of approximately $209.5 million and a runway through 2027 after dosing the first patient with PM577a and receiving FDA clearance for PM647.
Prime Medicine priced 35,714,286 shares at $3.50 per share and granted underwriters an option for 5,357,142 additional shares. Estimated net proceeds, including full option exercise and after underwriting discounts, commissions and offering expenses, are approximately $134.7 million.
Prime Medicine estimated cash, cash equivalents and short-term investments of approximately $61.2 million as of September 30, 2026, excluding approximately $13.7 million of restricted cash; the unaudited figures remained subject to quarter-end closing adjustments.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, investments and restricted cash | $108.8M | 6/30/2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRME
this stock
Prime Medicine, Inc.
|
$698.58M | +10.7% | +55.3% | — | 16.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 22
Prime Medicine expects first approval next year for chronic granulomous disease; Wilson disease Phase 1-2 began dosing in October and targets 2027 data, while alpha-1 antitrypsin’s first patient dose is expected end of the year or soon after.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRME | -1.3% | +3.0% | +12.9% | -18.6% | +10.7% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +4.2% | +9.2% | +18.6% | -13.4% | +5.7% |